Format

Send to:

Choose Destination
See comment in PubMed Commons below
Biologics. 2007 Dec;1(4):393-406.

Targeted therapies in the management of metastatic bladder cancer.

Author information

  • 1Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.

Abstract

The management of metastatic urothelial carcinoma (UC) of the bladder is a common and complex clinical challenge. Despite the fact that UC is one of the most frequent tumors in the population, long term survival for metastatic disease remains low, and chemotherapy is curative for only a small minority of patients. UC is genetically heterogeneous, and it is surrounded by a complex tissue microenvironment. The problems of clinical practice in the field of metastatic bladder cancer have begun to stimulate translational research. Advances in the understanding of the molecular biology of urothelial cancer continue to contribute to the identification of molecular pathways upon which new therapeutic approaches can be targeted. New agents and strategies have recently been developed which can direct the most appropriate choice of treatment for advanced disease. A review of literature published on the targeted therapy for metastatic bladder cancer is presented, focusing on the molecular pathways shut down by the new therapeutic agents.

KEYWORDS:

bladder cancer; gene targeting; gene therapy; metastasis; molecular biology

PMID:
19707309
[PubMed]
PMCID:
PMC2721287
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk